DocumentsDate added
RESEARCH ARTICLE
Mustafa Abdelgadir Khandgawi Ibrahim*,Adel Nasr Morsi,Liza Hamdi Mohamed
Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Sudan
Address reprint requests to
*Mustafa Abdelgadir Khandgawi Ibrahim,
Department of Chemical Pathology,Faculty of Medical Laboratory Sciences, Sudan, Khartoum
Article citation: Ibrahim MAK, Morsi AN, Mohamed, LH. Lipid profiles in Sudanese women with polycystic ovary syndrome. J Pharm Biomed Sci 2016;06(05):301–303.Available at www.jpbms.info
ABSTRACT
Background Polycystic ovary syndrome (PCOS) has been one of the important public health problems in Sudan, which leads to medical consequences and ends up in sterility.
Methods This study includes 40 PCOS women with age ranged between 16 and 40 years were selected based on Rotterdam criteria 2003 and 40 ovulatory normal non-PCOs, healthy and age-matched women as control. The lipid profiles (total cholesterol, LDL-C, HDL-C and triglyceride [TG]) were measured by an enzymatic colorimetric method using biosystem reagents. The data management and analysis were done with SPSS version 22.
Results There was no significant difference between the two groups in terms of age and body mass index except TG in PCOS ladies with BMI more than 25 was significantly higher in comparison with non-PCOs.
Conclusion This study does not guide the belief that PCOS affects serum lipid ranges, besides in the term of TG in PCOS girls with BMI >25. It is far advised to do this study in ladies with PCOS sufferers from insulin resistance.
KEYWORDS lipid profiles, PCOS, Sudanese women
References:
1.Iuhas C, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Appl Med Informatics. 2012;31(4):27–32.
2.Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertil Soc J. 2011;16(1):19–37.
3.Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883–96.
4.Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in polycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148–54.
5.Iuhas CI, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Appl Med Inform Origin Res.2012;31:27–32.
6.Rizzo M, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol. 2008;198:28–5.
7.Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case–control study. J Clin Endocrinol Metab. 2008;93:470–6.
8.Amini L, Sadeghi MR, Oskuie F, Kamali K, Maleki H. Lipid profile in women with polycystic ovary syndrome. Crescent J Med Biol Sci. 2014;1(4):147–50.
9.Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P,et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58:151–4.
10.Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in olycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148–54.
11.Latha M, Bhaskar MV, Sharma SSB, Sumapreethi A. Evaluation of dyslipidemia and oxidative stress in patients with polycystic ovarian syndrome. J Evol Med Dent Sci. 2012;1(5):769–775.
12.Shoaib O, Mustafa S, Nourein I. Serum lipid profile of polycystic ovary syndrome in Sudanese women. Int J Med Sci Public Heal [Internet]. 2015;4(11):1.
13.Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M,et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003;88:4682–8.
14.Savic S, Zarkovic M, Ciric M, Beleslin B, Drezgic M, Trbojevic B.Lipid profile in normal weight and obese women with polycystic ovary syndrome. Endocr Abstracts. 2006;11:341.
15.Bachceci M, aydemir M, Tuzcu A. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril. 2007;87:1363–8.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgments: The authors are thankful to the respected Prof. Mohamed Tageldin Ibrahim Omer and Dr. Omer Balla Ibrahim for guiding them in statistical analysis.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Hamoud Khalid Alshaya1,Saleh Ahmed Alogla1,Khalid Sukhail G. Alshammari1,Carlo L. Nazareno2, Mohammad AbdulazizSaud AlJameel2,Ashfaque Hossain1,2*
1 College of Medicine, University of Hail,Hail, Saudi Arabia
2 Center for Molecular Diagnostics and Personalised Therapeutics, University of Hail, Hail, Saudi Arabia
Address reprint requests to
*Ashfaque Hossain, PhD, Department of Microbiology, College of Medicine, University of Hail, Hail, Saudi Arabia
Article citation: Alshaya HK, Alogla SA, Alshammari KSG, Nazareno CL, AlJameel MAS, Hossain A. Isolation and characterisation of bacterial species from patients with dental caries and caries-free subjects. J Pharm Biomed Sci 2016;06(05):333–337.Available at www.jpbms.info
ABSTRACT
Background The oral cavity harbours a large number of bacterial species as normal flora existing as biofilm. Dental disease such as dental caries results when there is a shift in the balance of bacteria towards pathogenic species within these biofilms.
Objective The objective of this study was to isolation, identification and characterisation of oral bacterial species of patients with dental caries and caries-free healthy control subjects.
Materials and Methods A standard bacteriological procedures were followed in the isolation of bacteria. The identification of bacteria was carried out using matrix-associated laser desorption ionisation–time of flight–mass spectrometry (MALDI–TOF–MS) (Bruker MALDI Biotyper system). The characterisation of bacteria involved in the determination of biofilm forming potential and assessment of synergistic antimicrobial action of manuka honey and gentamicin against the oral species.
Results A total of 13 bacterial species were isolated from 35 orals samples (10 from patients with dental caries); of which seven bacterial species have been isolated for the first time in Saudi Arabia. The Streptococcus spp. exhibited varied biofilm-forming potential and response to synergistic antimicrobial activity of manuka honey and gentamicin.
Conclusion The isolation of seven bacterial species for the first time from dental caries and caries-free subjects in Saudi Arabia warrants a larger prevalence study involving molecular and phenotypic tests to assess their role in health and disease in Saudi population.
KEYWORDS dental caries, biofilm, oral microbiology, streptococcus, gentamicin, MALDI–TOF–MS
Acknowledgments: This study was supported by a grant from the Dean ship of Scientific Research, University of Hail to Dr.Ashfaque Hossain.
REFERENCES
1.Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev. 2000;13:547–558.
2.Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193.
3.Samaranayake LP. Normal oral flora, the oral ecosystem and plaque biofilm: essential microbiology for dentistry. Elsevier: Philadelphia; 2006. pp. 255–266.
4.Marsh PD. Dental plaque as a biofilm and a microbial community:implications for health and disease. BMC Oral Health. 2006;6:S14.
5.Mendelson MH, Gurtman A, Szabo S, Neibart E, Meyers BR,Policar M, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis. 1994;18:886–895.
6.Deep A, Chaudhary U, Gupta V. Quorum sensing and bacterial pathogenicity: from molecules to disease. J Lab Physicians.2011;3:4–11.
7.Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;43:S95–S99.
8.Karayil S, Deshpande SD, Koppikar GV. Effect of honey on multidrugresistant organisms and its synergistic action with three common antibiotics. J Postgrad Med. 1998;44:93–96.
9.Al-Jabri AA, Al-Hosni SA, Nzeako BC. Antibacterial activity of Omanihoney alone and in combination with gentamicin. Saudi Med J. 2005;26:767–771.
10.Mukherjee S, Chaki S, Das S, Sen S, Dutta SK, Dastidar SG. Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa. Indian J. Exp. Biol. 2011; 49: 547–51.
11.Jenkins RE, Cooper RA. Synergy between oxacillin and manuka honey sensitizes methicillin-resistant Staphylococcus aureus to oxacillin. J AntimicrobChemother. 2012;67:1405–1407.
12.van Veen SQ, Claas ECJ, Kuijper EdJ. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization- time of flight mass spectrometry in conventional medical microbiology laboratories. J Clin Microbiol. 2010;48:900–907.
13.Wieser A, Schneider L, Jung J, Schubert S. MALDI–TOF–MS in microbiological diagnostics: identification and beyond. J Appl Biotechnol. 2010;93:965–974.
14.Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–1922.
15.Pilhstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases.Lancet. 2005;366:1809–1820.
16.Selwitz RH, Ismail AI, Pitts NB. Dental caries. Lancet. 2007;369:51–59.
17.Zaura E, Keijser BJ, Huse SM, Crielaard W. Defining the healthy core microbiome of oral microbial communities. BMC Microbiol.2009;9:259.
18.Bik EM, Long CD, Armitage GC, Loomer P, Emerson J, Mongodin EF, et al. Bacterial diversity in the oral cavity of 10 healthy individuals.ISME J. 2010;4:962–974.
19.Amoroso P, de Ávila FA, Gagliardi CMO. Prevalence of different Streptococci species in the oral cavity of children and adolescents. Braz J Oral Sci. 2003;2:164–168.
20.Gross EL, Beall CJ, Kutsch SR, Firestone ND, Leys EJ, Griffen AL.Beyond Streptococcus mutans: dental caries onset linked to multiple species by 16S rRNA community analysis. PLoS ONE.2012;7:e47722.
21.Thurnheer T, Gmur R, Giertsen E, Guggenheim B. Automated fluorescent in situ hybridization for the specific detection and quantification of oral streptococci in dental plaque. J Microbiol Methods. 2001;44:39–47.
22.Sanchez MC, Llama-Palacios A, Blanc V, Leo´n R, Herrera D, Sanz M. Structure, viability and bacterial kinetics of an in vitro biofilm model using six bacteria from the subgingival microbiota.J Periodont Res. 2011;46:252–260.
23.Wecke J, Kersten T, Madela K, Moter A, Gobel UB, Friedmann A, et al. A novel technique for monitoring the development of bacterial biofilms in human periodontal pockets. FEMS Microbiol Lett. 2000;191:95–101.
24.Khan ST, Ahmad J, Ahamed M, Musarrat J, Al-Khedhairy AA. Zinc oxide and titanium dioxide nanoparticles induce oxidative stress, inhibit growth, and attenuate biofilm formation activity of Streptococcus mitis. J Biol Inorg Chem. 2016;21(3):295–303.
Statement of originality of work: The manuscript has been read and approved by all the authors. The requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Ye Qiumian1†,Ye Xiaocui2†,Luo Rui1†, Ou Jinlai2,Xu Zhenxia1,Zhao Wen1,Li Sha1*
1 Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Sunshine Lake Pharma Co., Ltd., Shenzhen 518000, China
† Ye Qiumian, Ye Xiaocui and Luo Rui contributed equally to this work
Address reprint requests to
*Li Sha, Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
Article citation: Qiumian Y, Xiaocui Y, Rui L, Jinlai O, Zhenxia X, Wen Z, Sha L. In vitro antifungal activity of pluronic-based thermo-sensitive itraconazole gels for vaginal administration. J Pharm Biomed Sci 2016;06(05):343–346.Available at www.jpbms.info
Abstract:
Vulvovaginal candidiasis (VVC) is a common genital disease disturbing women. ITZ is widely used for the treatment of VVC by oral administration in clinic. Due to its irregular absorption and systematic side effects, local administration of ITZ may be a preferred alternative for VVC treatment. The aim of this study was to investigate the in vitro antifungal activity of pluronic-based thermo-sensitive gels (TSG) of itraconazole (ITZ) for vaginal administration. 3-(4,5-2-yl)-2,5-diphenyltetrazolium bromide method was used to evaluate the antifungal activity of the ITZ-TSG against major microorganisms inducing vulvovaginal candidosis. The gelation temperature of ITZ-TSG was 25 and 35°C before and after the dilution of simulated vaginal fluid. Compared with ITZ, ITZ-TSG demonstrated effective antifungal activity and the gel vehicle showed no action. It suggested that ITZ-TSG may be a good candidate for vulvovaginal candidosis treatment.
KEYWORDS itraconazole, thermosentitive gels, antifungal activity in vitro, vaginal administration.
REFERENCES
1.Keller KA. Therapeutic review. J Exotic Pet Med. 2011;20(2):156–60.
2.Francois M, Snoeckx E, Putteman P, Wouters F, De Proost E,Delaet U, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci. 2003;5(1):50–54.
3.Xiao-cui YE, Jin-lai OU, Bao-xian H, Cui-juan F, Sha L. Preparation and characteristics of itraconazole vaginalthermosensitive in situ gels. J Cent South Pharm. 2014;12(6):551–556.
4.Zhang HH, Luo QH, Yang ZJ, Pan WS, Nie SF. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Deliv. 2011;18(7):502–10.
5.das Neves J. Vaginal delivery of biopharmaceuticals. In: das Neves J, Sarmento B (eds). Mucosal delivery of biopharmaceuticals:biology, challenges and strategies, Springer: New York;2014. pp. 261–80.
6.Yi Y, Yoon HJ, Kim BO, Shim M, Kim SO, Hwang SJ, et al. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J Control Release. 2007;117(1):59–67.
7.Odds FC. Itraconazole: a new oral antifungal agent with a very broad spectrum of activity in superficial and systemic mycoses. J Dermatol Sci. 1993;5(2):65–72.
8.Sobel JD, Faro S, Force RW. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–211.
9.Sinem Y, Seda R, Zeynep AY, Esra B. A new in-situ gel formulation of itraconazole for vaginal administration. Pharmacol Pharm. 2012;3:417–426.
10.Gupta A, Bluhm R. Itraconazole (Sporanox®) for vulvovaginal candidiasis. Skin Ther lett. 2001;7:1–3.
11.Fang T, Yu-zhu W, Kai Y, Cheng-li W, Qian-qian C, Wei-hua LI, et al. Rheological characteristics of nifeviroc vaginal thermosensitive in situ gels. Chin J New Drugs. 2013;22(3):345–350.
12.Cheng-wei W, Xing T, Xiao-mei W, Xiao-lin T, Zhen LI. Preparation of temperature-sensitive nonoxynol-9 sustained-release gel for vagina. Chin J New Drugs. 2006;15(4):281–284.
13.Puxiang C, Shangrong F. Development in classification, mycology and treatment of vulvovaginal candidiasis. Foreign Med Sci.2005;16(4):235–237.
14.Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE.Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl- 2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol. 2000;38(8):2949–54.
15.Genyan L, Wangsheng Z. In vitro drug sensitivity test of pathogenic fungi. J Clin Labor. 2011;06:406–409.
16.Yangjun S. In vitro interaction research of tetrandrine combined with azole antifungal agents. Jinan Univ. 2013.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of support: This research was supported by High Level University Construction Project (88015006).
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research,
patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Gong Tian1†,Zhou Guifang1†,Ye Qiumian1,Kuang Jianyuan1,Ou Jinlai2,Xu Zhenxia1,Zhao Wen1,Li Sha1*
1 Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Department of Preparation, Sunshinelake Pharma Co., LTD., Shenzhen 523871,China
† Both the authors contributed equally to this work
Address reprint requests to
*Li Sha, Department of Pharmaceutics,College of Pharmacy, Jinan University,Guangzhou 510632, China
Article citation: Tian G, Guifang Z,Qiumian Y, Jianyuan K, Jinlai O, Zhenxia X,Wen Z, Sha L. In vitro anticancer activity of doxorubicin-loading pectin nanoparticles. J Pharm Biomed Sci 2016;06(05):338–342.Available at www.jpbms.info
BSTRACT
By using pectin (PEC) as carrier material and doxorubicin (DOX) as a model drug, the blank PEC nanoparticles (PEC-NPs) and the DOX-loading PEC nanoparticles (DOX-PEC-NPs) were prepared by microemulsification method and drug adsorption. The aim of this study is to investigate the anticancer activity of DOX-PEC-NPs in vitro to understand the advantages of PEC-NPs as an anticancer drug delivery system. The particle size, polydispersity index (PDI) and zeta potential of PEC-NPs were (276.80 ± 2.80) nm, (0.140 ± 0.014) and (−19.83 ± 0.21) mV, while those of DOX-PEC-NPs were (283.73 ± 3.26) nm, (0.157 ± 0.034) and (−18.00 ± 0.44) mV. The entrapment efficiency (EE%) and drug-loading rate (LR%) of DOX-PEC-NPs were (92.10 ± 0.60)% and (18.72 ± 0.10)%, respectively. Using an MTT assay, the DOX-PEC-NPs were proved to greatly inhibit the viability of MDAMB-231 cells, A549 cells and NCI-H1299 cells, and the anticancer activity was higher than that of the DOX solution in these cells. The PEC-NPs had no cytotoxicity against the three tested cells. An inverted fluorescence microscope and flow cytometry were used to observe the intracellular uptake of DOX. The DOX-PEC-NPs resulted in faster and more DOX uptake than DOX solution in the tested cells. The results indicated that the PEC-NPs may be a potential anticancer drug delivery system which could reduce the dose and increase the activity of anticancer drugs.
KEYWORDS doxorubicin, pectin, nanoparticle, anticancer activity.
REFERENCES
1.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell.2000;100:57–70.
2.Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331–41.
3.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
4.Zhang N, Klegerman ME, Deng H, Shi Y, Golunski E, An Z.Trastuzumab–doxorubicin conjugate provides enhanced anticancer potency and reduced cardiotoxicity. J Cancer Ther. 2013;04:308–22.
5.Lei H, Wang X, Wu C. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations. J Mol Graph Model. 2012;38:279–89.
6.Evans AR, Miriyala S, St Clair DK, Butterfield DA, Robinson RA.Global effects of adriamycin treatment on mouse splenic protein levels. J Proteome Res. 2012;11:1054–64.
7.Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 2010;4:589–94.
8.Raj R, Das S. Prospects of bacteriotherapy with nanotechnology in nanoparticledrug conjugation approach for cancer therapy. Curr Med Chem. 2016;23:1477–94.
9.Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett. 2012;327:111–22.
10.Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007;96:1315–9.
11.Zhuang Y, Deng H, Su Y, He L, Wang R, Tong G, et al. Aptamerfunctionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapy. Biomacromolecules. 2016 [Epub ahead of print].
12.d’Ayala GG, Malinconico M, Laurienzo P. Marine derived polysaccharides for biomedical applications: chemical modification approaches. Molecules. 2008;13:2069–106.
13.Yuan Q, Venkatasubramanian R, Hein S, Misra RD. A stimulus- responsive magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-copolymer. Acta biomater. 2008;4:1024–37.
14.Liu L, Fishman ML, Hicks KB. Pectin in controlled drug delivery: a review. Cellulose. 2006;14:15–24.
15.Katav T, Liu L, Traitel T, Goldbart R, Wolfson M, Kost J. Modified pectin-based carrier for gene delivery: cellular barriers in gene delivery course. J Control Release. 2008;130:183–91.
16.Wen S, Ou J, Luo R, Liang W, OuYang P, Zeng F, et al. Preparation and release behavior of pectin nanoparticles loading doxorubicin. J Pharm Biomed Sci. 2015;5:385–93.
17.Ou J, Hong B, Ye X, Feng C, Gong T, Li S. Preparation and anti-tumor activity of doxorubicin-loading pectin nanoparticles in vitro. J Jinan Univ. 2014;35:330–6.
18.Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–8.
19. Yao F, Duan J, Wang Y, Zhang Y, Guo Y, Guo H, et al. Nanopore single-molecule analysis of DNA-doxorubicin interactions. Anal Chem. 2015;87:338–42.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of support: This research was supported by High Level University Construction Project (88015006).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
RESEARCH ARTICLE
Xiao-Mei Chen,Qing Wang, Rui-Kun He, Yu-Tao Li,Xiao-Yun Chen, Hiroshi Kurihara, Rong-Rong He, Yi-Fang Li*
Institute of Traditional Chinese Medicine and Natural Products, Jinan University,Guangzhou 510632, Guangdong, China
Address reprint requests to
*Yi-Fang Li, PhD, Institute of Traditional Chinese Medicine and Natural Products,Jinan University, Guangzhou 510632,Guangdong, China
Article citation: Chen XM, Wang Q, He RK, Li YT, Chen XY, Kurihara H, He RR,Li YF. Immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on murine antitumour effector cells. J Pharm Biomed Sci 2016;06(05):304–310.Available at www.jpbms.info
ABSTRACT
We investigated the immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on natural killer (NK) cells and lymphokine-activated killer (LAK) precursor cells from the spleens of C57BL/6 mice. Results showed that bleomycin and peplomycin can increase in vitro NK and LAK precursor cell activities both per spleen and per unit number (1 × 106 ) of the spleen cells as compared with normal mice from day 1 to 9,while the number of spleen cells did not increase. Meanwhile, a single administration of liblomycin caused a decrease in the number of spleen cells and the activity of LAK precursor cells per mouse spleen from day 1 and they recovered to normal levels by day 9.
NK activity, which was also suppressed by liblomycin, recovered slowly but failed to reach the complete restoration by day 9. Liblomycin showed no effect on LAK precursor cell activity per unit number of spleen cells. Further study showed that these immunomodulating effects of bleomycin and its derivatives are apparently at least partially mediated by the endogenous cytokine release.
KEYWORDS bleomycin, peplomycin, liblomycin, natural killer cell, lymphokine-activated killer precursor cell, cytokine
References:
1.Cragg GM, Kingston DGI, Newman DJ. Anticancer agents from natural products, 2nd ed., Boca Raton: CRC Press LLC;2005.
2.Abdul Hamied TA, Parker D, Turk JL. Potentiation of release of interleukin-2 by bleomycin. Immunopharmacology. 1986;12(2):127–134.
3.Hillel AT, Samad I, Ma G, Ding D, Sadtler K, Powell JD, et al. Dysregulated macrophages are present in bleomycin-induced murine laryngotracheal stenosis. Otolaryngol Head Neck Surg.2015;153(2):244–250.
4.Xu ZY, Hosokawa M, Morikawa K, Hatakeyama M, Kobayashi H.Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer Res.1988;8(23):6658–6663.
5.Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp Lung Res. 2015;41(2):57–73.
6.Takita T, Ogino T. Peplomycin and liblomycin, a new analogues of bleomycin. Biomed Pharmacother. 1987;41(5):219–226.
7.Takahashi K, Ekimoto H, Minamide S, Nishikawa K, Kuramochi H, Motegi A, et al. Liblomycin, a new analogue of bleomycin. Cancer Treat Rev. 1987;14(3–4):169–177.
8.Micallef M, Hosokawa M, Shibata T, Nakane A, Yang ZB,Minagawa T, et al. Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo. Cancer Immunol Immunother. 1991;33(1):33–38.
9.Ryzhkov VK, Zeidlits VN, Tikhonov KB. Use of protamine sulfate as a vasodilator in liver and spleen angiography. Vestn Rentgenol Radiol. 1977;(6):41–45.
10.Dresp J, Schmid E, Bauchinger M. The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo. Mutat Res. 1978;56(3):341–353.
11.Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG,Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med.2012;366:399–408.
12.Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ.Treatment of disseminated germ-cell tumors with cisplatin,bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–1440.
13.Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One. 2013;8(6):e65181.
14.Yoshida T, Ogawa M, Ota K, Yoshida Y, Wakui A, Oguro M, et al. Phase II study of NK313 in malignant lymphomas: an NK313 malignant lymphoma study group trial. Cancer Chemother Pharmacol. 1993;31(6):445–448.
15.Lazo JS, Braun ID, Labaree DC, Schisselbauer JC, Meandzija B, Newman RA, et al. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res. 1989;49(1):185–190.
16.Chen HY, Zheng CY, Zou GL, Xie DX, Gong JP. Peplomycin induces G1-phase specific apoptosis in liver carcinoma cell line Bel-7402 involving G2-phase arrest. Acta Pharmacol Sin.2004;25:1698–1704.
17.Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Haga T, Hashimoto A, et al. Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma. Dermatology. 2015;230(3):250–255.
18.Schwartz HS, Grindey GB. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 1973;33(8):1837–1844.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgment: The authors gratefully acknowledge the PhD, Masuo Hosokawa for supporting their work.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.